By a News Reporter-Staff News Editor at Drug Week -- A new study on Oncology is now available. According to news reporting out of Los Angeles, California, by NewsRx editors, research stated, "Pancreatic ductal adenocarcinoma is a devastating disease, with an overall 5-year survival rate of only 3% to 5%. As the current therapies offer very limited survival benefits, novel therapeutic strategies are urgently required to treat this disease."
Our news journalists obtained a quote from the research from the University of California, "Here, we determined whether metformin administration inhibits the growth of PANC-1 and MiaPaCa-2 tumor xenografts in vivo. Different xenograft models, including orthotopic implantation, were used to determine whether intraperitoneal or oral administration of metformin inhibits the growth of pancreatic cancer in vivo. We demonstrate that metformin given once daily intraperitoneally at various doses (50-250 mg/kg) to nude mice inhibited the growth of PANC-1 xenografts in a dose-dependent manner. A significant effect of metformin was obtained at 50 mg/kg and maximal effect at 200 mg/kg. Metformin administration also caused a significant reduction in the phosphorylation of ribosomal S6 protein and ERK in these xenografts. Metformin also inhibited the growth of pancreatic cancer xenografts when administered orally (2.5 mg/mL) either before or after tumor implantation. Importantly, oral administration of metformin also inhibited the growth of MiaPaCa-2 tumors xenografted orthotopically."
According to the news editors, the research concluded: "The studies presented here provide further evidence indicating that metformin offers a potential novel approach for pancreatic ductal adenocarcinoma prevention and therapy."
For more information on this research see: Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas, 2013;42(5):781-5. (Lippincott Williams and Wilkins - www.lww.com; Pancreas - journals.lww.com/pancreasjournal/pages/default.aspx)
Our news journalists report that additional information may be obtained by contacting K. Kisfalvi, Dept. of Medicine, Digestive Diseases Research Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, United States. Additional authors for this research include A. Moro, J. Sinnett-Smith, G. Eibl and E. Rozengurt (see also Oncology).
Keywords for this news article include: Oncology, California, Los Angeles, United States, Gastroenterology, Pancreatic Cancer, Pancreatic Neoplasms, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .